NCT05531786View on ClinicalTrials.gov

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

July 22, 2027

Study Completion Date

July 22, 2027

Conditions
Graft vs Host Disease
Interventions
DRUG

Pacritinib

Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.

Trial Locations (2)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

33101

RECRUITING

University of Miami, Miami

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH